GLI2 is a zinc-finger transcription factor involved in the Sonic Hedgehog pathway. Gli2 mutant mice have hypoplastic anterior and absent posterior pituitary glands. We reviewed the literature for patients with hypopituitarism and alterations in GLI2. Twenty-five patients (16 families) had heterozygous truncating mutations, and the phenotype frequently included GH deficiency, a small anterior pituitary lobe and an ectopic/undescended posterior pituitary lobe on magnetic resonance imaging and postaxial polydactyly. The inheritance pattern was autosomal dominant with incomplete penetrance and variable expressivity. The mutation was frequently inherited from an asymptomatic parent. Eleven patients had heterozygous non-synonymous GLI2 variants that were classified as variants of unknown significance, because they were either absent from or had a frequency lower than 0.001 in the databases. In these patients, the posterior pituitary was also ectopic, but none had polydactyly. A third group of variants found in patients with hypopituitarism were considered benign because their frequency was R0.001 in the databases. GLI2 is a large and polymorphic gene, and sequencing may identify variants whose interpretation may be difficult. Incomplete penetrance implies in the participation of other genetic and/or environmental factors. An interaction between Gli2 mutations and prenatal ethanol exposure has been demonstrated in mice dysmorphology. In conclusion, a relatively high frequency of GLI2 mutations and variants were identified in patients with congenital GH deficiency without other brain defects, and most of these patients presented with combined pituitary hormone deficiency and an ectopic posterior pituitary lobe. Future studies may clarify the relative role and frequency of GLI2 alterations in the aetiology of hypopituitarism. 
Introduction
This paper reviews the evidence for GLI2 mutations as a cause of hypopituitarism.
Hypopituitarism may manifest as a deficiency of a single pituitary hormone, such as isolated growth hormone deficiency (IGHD) or combined pituitary hormone deficiency (CPHD), and it may be congenital or acquired (Kelberman et al. 2009) . Congenital hypopituitarism may have a genetic, environmental or combined aetiology. Knowledge about genetic causes of congenital hypopituitarism has been advanced by the study of pituitary embryogenesis in animal models (natural and transgenic) and by candidate gene analysis in patients with pituitary hormone deficiencies. Although animal models have been very useful, one has to bear in mind that there may be differences when the results are extrapolated to the human (Kelberman et al. 2009 ).
GLI2 is a gene of the GLI-Kruppel family, which received its name because it was initially amplified in brain gliomas, and it is also known as GLI2 oncogene (OMIM*165230). GLI2 is located on the long arm of chromosome 2 at position q14 (genomic coordinates GRCh37: 2:121, 493, 750, 228) . The coding region is 6.8 kb in length and spans 13 exons which encode for the GLI2 protein with 1586 amino acids. GLI2 is a transcription factor that contains a zinc-finger region responsible for binding to DNA (aa437-594), an aminoterminal (-NH2) region with repressor activity and a carboxy-terminal (-COOH) domain responsible for transcriptional activation (Roessler et al. 2003 (Roessler et al. , 2005 . Gli2 is a member of the Gli family of proteins (including Gli1 and Gli3) which are involved in the Sonic Hedgehog (Shh) signalling pathway.
SHH (Shh, OMIM*600725) induces tissue-specific cellular proliferation during embryogenesis (Villavicencio et al. 2000) . After cleavage and the addition of a cholesterol molecule, Shh binds to the membrane receptor Patched releasing Smoothened, which in turn activates the Gli family of transcription factors. Gli1 and Gli2 usually act as activators, and Gli3 usually acts as a repressor; however, divergence of Gli protein function among tissues and species has been observed (Ruiz i Altaba et al. 2002) .
Role of the Shh/Gli2 pathway in pituitary embryogenesis
Most of our knowledge about pituitary embryogenesis derives from murine models. In mice, the development of the pituitary results from the timely complex interaction of transcription factors and signalling molecules acting as activators or repressors, which play a crucial role in cell proliferation, cell patterning and terminal differentiation (Zhu et al. 2007) . The posterior pituitary lobe derives from the neural ectoderm of the ventral diencephalon, which is part of the anterior neural placode, whereas the anterior lobe (and intermediate lobe in mice) derives from the oral ectoderm adjacent to the diencephalon (extensively reviewed by Kelberman et al. (2009) (Zhu et al. 2007 , Kelberman et al. 2009 ). The oral ectoderm thickens and invaginates upwards to form the Rathke's pouch, and the diencephalon evaginates downwards (Treier et al. 2001 ). Rathke's pouch separates and detaches from the oral ectoderm to form the pituitary gland.
During early vertebrate embryogenesis, Sonic Hedgehog (Shh, OMIM*600725) is expressed in midline tissues, such as the notochord and floor plate of the neural tube, and it is critical for distal elements of the developing limbs. Shh is expressed in the ventral diencephalon and in the adjacent oral ectoderm but not in the primordial Rathke's pouch (Treier et al. 2001) . In contrast, the Shh receptor Patched is expressed in Rathke's pouch. Shh signalling is mediated by three related zinc-finger transcription factors, Gli1, Gli2, and Gli3, which are expressed in the ventral diencephalon and in the developing Rathke's pouch and lead to activation of target genes (Hui et al. 1994) . Gli2 is expressed in the ventral diencephalon, where it induces Bmp4 and Fgf8 expression, and it is also expressed in the oral ectoderm, where it induces pituitary progenitors (Wang et al. 2010) . In mice, inactivation of Gli2 caused severe ventral patterning defects in the hindbrain, diminished pituitary progenitor cells, caused a normally patterned but hypoplastic anterior pituitary as a result of diminished cellular proliferation and reduced expression of Bmp4 and Fgf8 with an absent posterior lobe (Lebel et al. 2007 , Wang et al. 2010 . The numbers of somatotropes, lactotropes and corticotropes were also diminished (Wang et al. 2010) . In contrast, mice with inactivated Gli1 or Gli3 had no pituitary abnormalities (Wang et al. 2010) .
By in situ hybridisation and immunostaining, Gregory et al. (2015) showed widespread expression of GLI2 within the neural epithelium, including the hypothalamus, head mesenchyme and developing Rathke's pouch, in human embryos at Carnegie stages 13 and 15. Widespread Gli2 expression has previously been described in mouse embryos at comparable developmental stages (11-12 days post coitum) (Hui et al. 1994) , which demonstrates that GLI2 is expressed during human development at the critical stages when Gli2 activity is required in the mouse (Gregory et al. 2015) .
A mutant zebrafish with loss-of-function gli2 (yoo-too, yot) was shown to have anterior pituitary hypoplasia and abnormal patterning of the ventral CNS (Karlstrom et al. 2003) .
Human mutations
SHH mutations are a genetic cause of holoprosencephaly (HPE), which is characterised by a failure of midline division of the forebrain. Clinical manifestations are variable, ranging from closely spaced eyes (hypotelorism) to the failure of the eye field and forebrain to separate, which is associated with cyclopia (Roessler et al. 2003) . GLI2 is a mediator of SHH action and is, therefore, a candidate gene for HPE. Roessler et al. (2003 Roessler et al. ( , 2005 isolated the human GLI2 gene and searched for mutations in 390 patients who met clinical criteria for HPE. Very few patients had GLI2 mutations that, in addition to HPE, were noted to have polydactyly, midfacial and/or pituitary abnormalities. The authors observed an autosomal dominant inheritance with incomplete penetrance and inferred that pituitary and facial structures were more sensitive to a reduction in GLI2 activity than the ventral forebrain was. Subsequently, Rahimov et al. (2006) screened GLI2 in patients with isolated midfacial defects, and França et al. (2010) screened patients with isolated pituitary hormone deficiency without HPE. In this review, we concentrate on the GLI2 mutations in patients that have a pituitary phenotype with or without additional abnormalities.
A comprehensive review of GLI2 mutations also in subjects without hypopituitarism that included patients with HPE and/or midfacial defects or their normal relatives has been published by Bear et al. (2014) .
Several different heterozygous GLI2 variants have been reported in patients with hypopituitarism, and some of these variants have been reported in databases of normal individuals. It is not clear if all of them have clinical significance. GLI2 mutations with a functional effect may be found in normal individuals because the penetrance is incomplete and its percentage is presently unknown. Incomplete penetrance also indicates that the mutation alone is probably not enough to cause the phenotype but instead must be coupled to other genetic and/or environmental factors.
In this review, we take a conservative approach and classify variants in three groups: i) highly likely to cause the phenotype: complete gene deletions, nonsense or frameshift mutations that result in protein truncation, mutations in the universal splicing sites (K2, K1, C1 or C2) and mutations within the zinc-finger region with impaired functional test (Table 1) ; ii) variants of unknown significance: non-synonymous variants with normal or absence of functional tests but absent or with an allele frequency lower than 0.001 in Exome Variant Server (EVS) and Exome Aggregation Consortium (ExAC browser, http://exac.broadinstitute.org; updated 18/02/2015) and/or local control individuals (Table 2) ; and iii) probably benign: variants with a frequency R0.001 (equivalent to 0.1%) in the EVS or ExAC browser. Table 1 displays 25 patients from 16 families where the GLI2 mutation has led to a severe alteration in the GLI2 protein, including: one family with a complete gene deletion, six with termination codons, six with frameshift mutations that resulted in stop codons, one with a mutation in the universal splicing site and two with mutations in the zinc-finger region and functional tests that show impaired transactivation. Roessler et al. (2005) performed luciferase-based reporter assays in cultured mouse C3H cells to test GLI2 transcriptional activity. The human GLI2 carboxyterminal domain had transcriptional activity, whereas the amino-terminal domain had transcriptional repressor activity, which was similar to reported findings in mice Gli2 (Sasaki et al. 1999 , Roessler et al. 2005 . Constructs that represent pathogenic human GLI2 mutants with intact amino-terminal and zinc-finger domains and a truncated carboxy-terminal domain showed no intrinsic Gli2 transcriptional activity. Cotransfection of these mutants, together with WT GLI2, revealed strong dominant negative activity as compared to WT alone. Intact zinc-finger as well as amino-terminal domains were important for the preservation of dominant negative activity (Roessler et al. 2005) . The GLI2 p.Arg516Pro mutation reported by Flemming et al. (2013) in patient 4a is located in the third zinc finger of the DNA-binding domain. Electromobility shift assay demonstrated a lack of binding to a consensus GLI-binding site, and luciferase reporter assay revealed a complete loss of transactivation in mouse embryonic fibroblast (NIH-3T3) as well as murine corticotrophinoma (At-T 20) cell systems. Further experiments showed no dominant negative behaviour of this mutation, which confirmed previous studies that required integrity of the DNA-binding domain for this effect (Roessler et al. 2005 , Flemming et al. 2013 . The authors suggested a dose effect or even autosomal random monoallelic expression. The two-amino-acid-apart GLI2 p.Glu518Lys mutation reported by Gregory et al. (2015) had normal binding on the electromobility shift assay but Table 1 had polydactyly, whereas none of the patients in Table 2 had polydactyly, which suggests that only major GLI2 abnormalities result in polydactyly. Similar findings have been observed by Bear et al. (2014) : 16/26 (62%) of severe mutations had polydactyly in addition to pituitary abnormalities, whereas only 1/58 (2%) with milder variants had both hand and pituitary defects. The presence of polydactyly in a patient with hypopituitarism or in one of his relatives may be an additional indication that the GLI2 gene should be studied (França et al. 2010) . Interestingly, mice with targeted disruption of Gli2 have not been shown to have digit abnormalities unless Gli1 is also deleted, which emphasizes the difference between Gli protein functions in vertebral species (Roessler et al. 2005) .
Molecular testing was performed in several parents of the probands with hypopituitarism in Table 1 : of the 11 parents who carried the same mutation, two had hypopituitarism (one with polydactyly), three had only polydactyly and six were apparently completely normal. This indicates that even with the most severe mutations, the penetrance is incomplete. Therefore, in addition to the GLI2 mutation, another genetic and/or environmental factor is probably responsible for the pituitary phenotype.
An interaction between specific genetic and environmental risk factors has been demonstrated in mice by Kietzman et al. (2014) . Heterozygous Shh and Gli2 mice exposed to prenatal ethanol had, respectively, a 3.2-and a 6.6-fold increase in their dysmorphology score as compared to WT littermates that were exposed to the same ethanol protocol. The authors also observed a close correlation between the severity of facial dysmorphology and midline forebrain abnormalities in affected animals (Kietzman et al. 2014) .
The phenotypic expressivity of GLI2 mutations is variable. The largest family with GLI2 mutations reported to date had the p.Leu788fsX794 mutation (França et al. 2010 , Paulo et al. 2015 . In the family reported by França et al. (2010) , the ten subjects who tested positive for the mutation also had polydactyly, whereas in the two distant relatives with the same mutation studied by Paulo et al. (2015) in a different city, polydactyly was not observed. Among the six patients with hypopituitarism, four had IGHD and two had CPHD, independent of age. The two patients reported by Paulo et al (2015) . had a median solitary maxillary incisor, one with cleft palate, but this was not observed in the patients studied by França et al (2010) . Therefore, the phenotypic variability in this family with the same mutation ranged from polydactyly only to IGHD or CPHD, with the presence or absence of cleft palate and of a median solitary maxillary incisor. None of the patients had brain abnormalities characteristic of HPE. Interestingly, all of the patients with hypopituitarism in this family had a small anterior lobe and an ectopic posterior lobe on pituitary magnetic resonance imaging (MRI).
After an extensive review of more than 400 patients, Bear et al. (2014) concluded that frank HPE resulting from pathogenic GLI2 mutations is rare. The absence of forebrain abnormalities in patients with GLI2 mutations, as opposed to those with SHH mutations, might be related to the maintained activity of GLI3 in the former. Shhdependent ventral patterning in the neural tube is preserved in Gli1/Gli2 double homozygous mutant mice embryos, which suggests that Gli3 partly compensates for the function of Gli2 (Sasaki et al. 1999 ).
An ectopic or undescended posterior pituitary lobe is a frequent finding in patients with hypopituitarism resulting from GLI2 mutations. An ectopic or undescended posterior pituitary lobe is also a frequent finding in patients with GH deficiency, especially CPHD. Its presence on MRI has been increasingly used for the diagnosis of (Diaczok et al. 2008 , Dateki et al. 2010 . In addition, mutations in these early acting factors may present as part of a syndrome in patients that manifest abnormalities in extra-pituitary structures that share a common embryological origin with the pituitary gland, such as the eye and forebrain. However, mutations in these factors have been identified in only a minority of patients that have hypopituitarism with an ectopic posterior lobe, and GLI2 mutations might be a significant genetic cause of additional cases (França et al. 2013) .
Mutations in PROP1 are the most common genetic cause of CPHD in many geographical areas, but the inheritance is autosomal recessive with complete penetrance, and in all patients, the posterior pituitary lobe has been shown to have a normal position (Wu et al. 1998 , Kelberman et al. 2009 ). Interestingly, the posterior pituitary lobe has been consistently in a normal position in patients with mutations in transcription factors that act late, and expression is restricted to the Rathke's pouch, such as PROP1 and POU1F1 (PIT1) (Alatzoglou & Dattani 2009 ).
Two patients (2a and 27a, Tables 1 and 2) also had diabetes insipidus. ADH deficiency might be explained because GLI2 is also expressed in the ventral diencephalon, and it is important for hypothalamus, infundibulum and posterior pituitary lobe formation (Wang et al. 2010) . All of the mice with Gli2 mutations had no posterior pituitary, which suggests that Gli2 is a requirement for ventral diencephalon formation (Wang et al. 2010) . Interestingly, patient 2a with a nonsense mutation (p.E380X) had diabetes insipidus at the age of 18 months and reached a urinary osmolality of 613 mOsm/kg H 2 O during follow-up at the age of 30 months (França et al. 2010) .
In one patient, diabetes insipidus and semilobar HPE were initially attributed to a GLI2 p.Arg226His variant (Roessler et al. 2003) . However, the patient was later found to also have a truncating mutation in ZIC2, and there was stronger evidence that this was the cause of HPE and ADH deficiency in that individual (Solomon et al. 2009 ).
Diabetes insipidus is common in typical HPE, whereas in patients with GLI2 mutations, there is frequent anterior pituitary hormone deficiency (Bear et al. 2014) .
It is noteworthy that patient 27a with the GLI2 p.Gly947Asp variant had, in addition to hypopituitarism, incomplete masculinisation of the external genitalia. Miyagawa et al. (2011) have shown that Shh is expressed in the urethral plate epithelium of mice during embryogenesis and that its signal is mediated through Gli2 in the mesenchyme. Gli2 mutants had hypoplasia of the genital tubercle and a cleft at the proximal ventral midline without androgen deficiency. This murine phenotype resembles that patient's hypospadias. However, the boys with other GLI2 sequence variants or nonsense mutations had normal external genitalia, which indicates that additional, as-yet-unidentified factors modulate the phenotype.
The greater prevalence of GH deficiency among hypopituitary patients that harbour GLI2 mutations might be explained by an ascertainment bias, because more cohorts of patients with GH deficiency have been studied. Furthermore, Gli2 knockout mice have a reduced number of somatotrophs, and these represent the largest population of pituitary hormone-secreting cells (Wang et al. 2010) . Vaaralahti et al. (2012) screened HPE genes in 19 patients with Kallman syndrome who were negative for known candidate gene mutations. One patient (25a, Table 2 ) had the GLI2 p.Glu837Lys variant (Table 2) in addition to a SIX3 p.Gly143Asp. He had gonadotrophin deficiency but no evidence of other characteristics of patients with GLI2 mutations, such as GH hormone deficiency, ectopic posterior pituitary lobe or polydactyly. Although the pathogenicity of these variants was not proven, the authors suggested an overlap between HPE and Kallman syndrome genes.
Larger deletions of chromosome 2q, including GLI2 and several additional genes, have been described. Kevelam et al. (2012) reported a heterozygous submicroscopic 1.3 kb deletion of 2q14.2 in a patient with a cleft lip and palate and panhypopituitarism. Gustavsson et al. (2006) described a balanced translocation and a Table 3 shows heterozygous non-synonymous GLI2 variants that were reported in isolation or in combination in patients with hypopituitarism and were probably benign, because their frequency in updated databases of normal individuals was R0.001. However, the 0.001 threshold is arbitrary, because the true prevalence of hypopituitarism resulting from GLI2 mutations is unknown, as is the penetrance of GLI2 mutations, which may also vary according to each specific mutation. Therefore, it is premature to conclude that these variants have no effect on the phenotype. Functional studies are useful, but they also have limitations because of their artificial nature. It is possible that after a few years of whole exome and genome sequencing of large cohorts of patients with hypopituitarism, the relative contribution of variants in different genes will be better understood. There is also a selection bias of the types of patients that are screened with the candidate gene approach. Because the GLI2 gene will be included in the analysis in different conditions that are submitted to whole exome/genome sequencing in future studies, the range of phenotypes associated with each GLI2 mutation will likely be further expanded.
The exact frequency of GLI2 alterations in patients with hypopituitarism is still difficult to determine because of the ascertainment bias in and the phenotypic heterogeneity of studied patient cohorts as well as different GLI2 screening methods and a lack of proof of pathogenicity for many GLI2 variants. Among 284 patients with hypopituitarism from three cohorts in whom the complete coding region of GLI2 was sequenced, 15 patients (5%) had either loss-of-function or non-synonymous GLI2 variants found in updated databases with a frequency lower than 0.001 (França et al. 2013 , Gregory et al. 2015 , Paulo et al. 2015 .
The aetiology of congenital GH deficiency in most cases is still unknown. The presence of familial cases suggests a genetic origin instead of a traumatic/ischaemic origin secondary to perinatal insults (Phillips & Cogan 1994 , Triulzi et al. 1994 . However, in most cases of GH deficiency, the family history is apparently not positive for similar cases. A disease model of partial penetrance, as with GLI2 mutations, indicates that the possibility of hypopituitarism and/or polydactyly should be investigated even in distant relatives. One of the index patients had two uncles with IGHD who were unaware of their condition (França et al. 2010) .
GLI2 is a large and polymorphic gene, and sequencing may identify variants of unknown significance whose interpretation may be difficult. GLI2 variants might interact with environmental and other genetic factors to modulate the phenotype. Functional analyses of GLI2 variants are important to add evidence to their pathogenicity.
In conclusion, a relatively high frequency of GLI2 mutations and variants was identified in patients with congenital GH deficiency without other brain defects, and most of these patients presented with CPHD and an ectopic posterior pituitary lobe. Future studies may clarify the relative role and frequency of GLI2 alterations in the aetiology of hypopituitarism.
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